SCHEMBL21048476

SCHEMBL21048476

Cc1ccccc1-c1n[nH]c2ncnc(N)c12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 8/20 0.59
PIK3CD O00329 8/20 0.59
PIK3CA P42336 7/20 0.59
PIK3CB P42338 7/20 0.59
PRKDC P78527 7/20 0.59
EGFR P00533 1/20 0.46
CDK1 P06493 1/20 0.46
SRC P12931 1/20 0.46
BTK Q06187 1/20 0.43
EPHA4 P54764 1/20 0.42
RIPK2 O43353 1/20 0.41
HTR7 P34969 1/20 0.40
FFAR2 O15552 1/20 0.39
DCUN1D1 Q96GG9 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
ALOX15 P16050 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30387798 0.88 PIK3CD (0.61) PIK3CGPIK3CDPIK3CAPIK3CBPRKDC
SCHEMBL27774340 0.82 PIK3CD (0.59) PIK3CGPIK3CDPIK3CAPIK3CBPRKDC
SCHEMBL30386850 0.82 PIK3CD (0.59) PIK3CGPIK3CDPIK3CAPIK3CBPRKDC
SCHEMBL19414364 0.78 SRC (0.43) PIK3CGPIK3CDPIK3CAPIK3CBPRKDC
SCHEMBL408618 0.78 PIK3CD (0.55) PIK3CGPIK3CDPIK3CAPIK3CBPRKDC
SCHEMBL19385334 0.76 LCK (0.47) PIK3CGPIK3CDPIK3CAPIK3CBPRKDC
SCHEMBL3782102 0.75 PIK3CD (0.57) PIK3CGPIK3CDPIK3CAPIK3CBPRKDC
SCHEMBL5065122 0.75 PIK3CD (0.57) PIK3CGPIK3CDPIK3CAPIK3CBPRKDC
SCHEMBL28959389 0.74 PRKD3 (0.58) EGFRHSD17B10CLK4
SCHEMBL30386858 0.74 PIK3CD (0.61) PIK3CGPIK3CDPIK3CAPIK3CBPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230111917-A1 KINASE ANTAGONISTS UNIV CALIFORNIA (US) 2023-04-13 US disclosed
EP-2551270-B1 PYRAZOLOPYRIMIDINE DERIVATIVES FOR USE AS PI3 KINASE ANTAGONISTS UNIV CALIFORNIA (US) 2019-06-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230111917-A1 KINASE ANTAGONISTS MTOR, RPS6KA3, AKT3 PIK3CG 30/4885PIK3CD 12/4885PIK3CA 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.